Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma

NCT05568641 | Unknown

• 1 other identifier: Soh-Med-22-09-12
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Laryngeal squamous cell carcinoma (LSCC) is the second most common primary malignant tumor of the respiratory tract after lung cancer and the second most common primary epithelial malignant tumor of the head and neck. The age of onset of LSCC is mostly between 50 and 70 years, with a male to female ratio of approximately 4:1 .According to estimates by the American Cancer Society, in the United States, approximately 12,470 new cases of laryngeal cancer will be diagnosed and 3,820 people will die from laryngeal cancer in 2022. The nuclear vitamin D receptor (VDR) is involved in multiple pathways that have many points of convergence. Some of these pathways are implicated in carcinogenesis thus the suggestion that VDR has a role to play in the biology of cancer \[3\]. Recent evidence indicates that the active form of vitamin D (1alpha, 25-dihydroxycholecalciferol) (VD) exhibits several different effects on normal and cancerous cells, including up-regulation of anti- proliferation and pro-apoptotic factors, as well as inhibition of cell-cycle promoters and growth factor signaling pathways. Thus it is useful as an anti-neoplastic agent in several human malignancies. Studies in cell and animal model systems, as well as clinical trials have recognized the potential usefulness of VD and VD analogues as agents that enhance the anti-proliferative/cytotoxic effects of chemotherapy and ionizing radiation. Thus, at concentrations that produce limited hypercalcemia, these agents may be used as adjuncts to conventional chemotherapy and radiotherapy. We aim to analyze the expression of VDR in LSCC to determine potential for active VD therapy in such patients.

Conditions

Laryngeal Carcinoma

Outcome Measures

Primary Outcomes (1)

• Diagnosis and prognosis of laryngeal squamous cell carcinoma

  Immunohistochemical Expression of Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma

  Two or three days after staining tissue sections with Vit D receptor antibody

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

A retrospective study will be carried out on 50 LSCC specimens that were collected randomly from archives of Pathology Department, Faculty of Medicine, Sohag University

You may qualify if:

• Both endoscopic and excisional biopsy specimens.
• All the studied cases include sufficient materials for the immunohistochemical study.
• Complete clinical data

You may not qualify if:

• Patients with recurrence of the primary tumor.
• Patients with a history of preoperative chemotherapy and/or radiotherapy.
• Insufficient or tiny tissue biopsies

Sponsors & Collaborators

• Sohag University: lead

MeSH Terms

Conditions

Laryngeal Neoplasms

Condition Hierarchy (Ancestors)

Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Laryngeal Diseases; Respiratory Tract Diseases; Respiratory Tract Neoplasms; Otorhinolaryngologic Diseases

Study Officials

• Amira A Abdelnaby, Lecturer

  Faculty of medicine ,Sohag university

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Amira A Abdelnaby, Lecturer

CONTACT

01002097612; ameraabdelnaby55@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of pathology

Study Record Dates

• First Submitted: October 2, 2022
• First Posted: October 5, 2022
• Study Start: January 1, 2023
• Primary Completion: January 1, 2023
• Study Completion: March 1, 2023
• Last Updated: January 18, 2023

Record last verified: 2023-01